subscribeSubscribe
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay
PR NEWSWIRE
13 Nov 2023
Share Share
Ipsen updates on E.U. MaAA for odevixibat in Alagille syndrome

Ipsen updates on E.U. MaAA for odevixibat in Alagille syndrome
GLOBENEWSWIRE
23 Oct 2023
Share Share
Albireo`s Bylvay (Odevixibat) Approved In Europe

Albireo`s Bylvay (Odevixibat) Approved In Europe
EMA
05 Jul 2023
Share Share
EQT Private Equity to sell Ellab, following transformation into a validation

EQT Private Equity to sell Ellab, following transformation into a validation
PR NEWSWIRE
21 Jun 2023
Share Share
Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in (PFIC)

Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in (PFIC)
PR NEWSWIRE
20 Jun 2023
Share Share
After Albireo buyout, Ipsen`s Bylvay picks up new use

After Albireo buyout, Ipsen`s Bylvay picks up new use
Eric Sagonowsky FIERCE PHARMA
14 Jun 2023
Share Share
Ipsen to present new Bylvay (odevixibat) data at annual ESPGHAN congress

Ipsen to present new Bylvay (odevixibat) data at annual ESPGHAN congress
GLOBENEWSWIRE
17 May 2023
Share Share
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA

Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA
GLOBENEWSWIRE
19 Dec 2022
Share Share
Reimbursed Access to Bylvay Approved in France for Patients with PFIC 1 & 2

Reimbursed Access to Bylvay Approved in France for Patients with PFIC 1 & 2
GLOBENEWSWIRE
30 Nov 2022
Share Share
Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022

Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022
GLOBENEWSWIRE
07 Nov 2022
Share Share